 NEW YORK, Jan. 5, 2021 PRNewswire -- Immunic, Inc. Nasdaq: IMUX, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced managements participation in the... 